

## เอกสารอ้างอิง

- (1) Jacobson KA, Jarvis MF, Williams M. Purine and pyrimidine (P2) receptors as drug targets. *J Med Chem* 2002; 45(19):4057-4093.
- (2) Burnstock G. Purinergic signalling. *Br J Pharmacol* 2006; 147 Suppl 1:S172-S181.
- (3) Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA et al. Nomenclature and classification of purinoceptors. *Pharmacol Rev* 1994; 46(2):143-156.
- (4) Ralevic V, Burnstock G. Receptors for purines and pyrimidines. *Pharmacol Rev* 1998; 50(3):413-492.
- (5) Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Seguela P et al. International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. *Pharmacol Rev* 2001; 53(1):107-118.
- (6) Roberts JA, Vial C, Digby HR, Agboh KC, Wen H, Atterbury-Thomas A et al. Molecular properties of P2X receptors. *Pflugers Arch* 2006; 452(5):486-500.
- (7) Vial C, Roberts JA, Evans RJ. Molecular properties of ATP-gated P2X receptor ion channels. *Trends Pharmacol Sci* 2004; 25(9):487-493.
- (8) Chizh BA, Illes P. P2X receptors and nociception. *Pharmacol Rev* 2001; 53(4):553-568.
- (9) Guo C, Masin M, Qureshi OS, Murrell-Lagnado RD. Evidence for functional P2X4/P2X7 heteromeric receptors. *Mol Pharmacol* 2007; 72(6):1447-1456.
- (10) Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C et al. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. *Pharmacol Rev* 2006; 58(3):281-341.
- (11) Fumagalli M, Trincavelli L, Lecca D, Martini C, Ciana P, Abbracchio MP. Cloning, pharmacological characterisation and distribution of the rat G-protein-coupled P2Y(13) receptor. *Biochem Pharmacol* 2004; 68(1):113-124.

- (12) Abbracchio MP, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT et al. Characterization of the UDP-glucose receptor (re-named here the P2Y<sub>14</sub> receptor) adds diversity to the P2Y receptor family. *Trends Pharmacol Sci* 2003; 24(2):52-55.
- (13) von Kugelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. *Pharmacol Ther* 2006; 110(3):415-432.
- (14) Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide receptor signaling in platelets. *J Thromb Haemost* 2006; 4(11):2317-2326.
- (15) Müller CE. P2-pyrimidinergic receptors and their ligands. *Curr Pharm Des* 2002; 8(26):2353-2369.
- (16) Fields RD, Burnstock G. Purinergic signalling in neuron-glia interactions. *Nat Rev Neurosci* 2006; 7(6):423-436.
- (17) Rettinger J, Schmalzing G, Damer S, Muller G, Nickel P, Lambrecht G. The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor. *Neuropharmacology* 2000; 39(11):2044-2053.
- (18) Wilkin F, Duhant X, Bruyns C, Suarez-Huerta N, Boeynaems J-M, Robaye B. The P2Y<sub>11</sub> Receptor Mediates the ATP-Derived Dendritic cells. *J. Immunol* 2001; 166: 7172-7177.
- (19) Vaughan KR et.al Inhibition of Neutrophil Apoptosis by ATP Is Mediated by the P2Y<sub>11</sub> Receptor. *J Immunol* 2007; 179; 8544 - 8553.
- (20) Greve H, Meis S, Kassack MU, Kehraus S, Krick A, Wright AD, König GM. New lanthanans from the Marine Sponges *Ianthella quadrangulata*: Novel Antagonist of the P2Y<sub>11</sub> Receptor. *J Med Chem* 2007; 50: 5600-5607
- (21) Meis S, Hamacher A, Hongwiset D, Marzian C, Wiese M, Eckstein N, Royer H-D, Communi D, Boeynaems J-M, Hausmann R, Schmalzing G, and Kassack MU. NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1 (4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-*l,l'*-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y<sub>11</sub> agonist and stimulates release of IL-8 from human monocyte-derived dendritic cells. *J Pharmacol Exp Ther.* 2010; 332: 238-247.

- (22) Ullmann H, Meis S, Hongwiset D, Marzian C, Wiese M, Nickel P et al. Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. *J Med Chem* 2005; 48(22):7040-7048.
- (23) Meis S, Hongwiset D, Kassack MU. Discovery of new potent, non-nucleotide ligands at human P2Y11-receptors results in NF546, the first non-nucleotide P2Y receptor agonist, and NF340, the so far most potent and selective P2Y11 antagonist. *Purinergic Signalling* 2006; 2(2):177.
- (24) Kassack MU, Hofgen B, Lehmann J, Eckstein N, Quillan JM, Sadee W. Functional screening of G protein-coupled receptors by measuring intracellular calcium with a fluorescence microplate reader. *J Biomol Screen* 2002; 7(3):233-246.



